on December 8, 2005
Published online before print December 8, 2005, doi: 10.1161/01.ATV.0000199268.27395.4f
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 20, 2005
Accepted on November 28, 2005
Smoking, Metallproteinases, and Vascular Disease
Todd S. Perlstein and Richard T. Lee *
From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Mass.
* To whom correspondence should be addressed. E-mail: rlee{at}rics.bwh.harvard.edu.
Abstract--Smoking causes up to 11% of total global cardiovascular deaths. Smoking has numerous effects that may promote atherosclerosis through vascular inflammation and oxidative stress, but the pathogenesis of smoking-related cardiovascular disease remains incompletely understood. The matrix metalloproteinases, a family of endopeptidases that can degrade extracellular matrix components in both physiological and pathophysiological states, play an important role in smoking-associated chronic obstructive pulmonary disease, the second leading cause of smoking attributable mortality. Emerging evidence indicates that the matrix metalloproteinases may also contribute to smoking-related vascular disease. Here we discuss the potential relationship between smoking, matrix metalloproteinases, and acceleration of vascular disease.
This article has been cited by other articles:
 |
|
 |
|
  A. Kifley, G. Liew, J. J. Wang, S. Kaushik, W. Smith, T. Y. Wong, and P. Mitchell Long-term Effects of Smoking on Retinal Microvascular Caliber Am. J. Epidemiol., December 1, 2007; 166(11): 1288 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kelly, G. Cockerill, L. L. Ng, M. Thompson, S. Khan, N. J. Samani, and I. B. Squire Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study Eur. Heart J., March 5, 2007; (2007) ehm003v1. [Abstract] [Full Text] [PDF]
|
|